

## **GMO INVESTMENTS ICAV**

**(an Irish collective asset-management vehicle having registration number C155870  
(the “ICAV”))**

### **AN UMBRELLA FUND WITH SEGREGATED LIABILITY BETWEEN SUB-FUNDS**

#### **UK COUNTRY SUPPLEMENT**

#### **ADDITIONAL INFORMATION FOR INVESTORS IN THE UK**

for

**GMO SGM Major Markets Investment Fund  
GMO Climate Change Investment Fund  
GMO Equity Dislocation Investment Fund  
GMO Emerging Country Debt UCITS Fund  
GMO Usonian Japan Value Fund  
GMO Resources UCITS Fund**

**DATED 6 April 2021**

**This document forms part of and should be read in conjunction with the prospectus for GMO SGM Major Markets Investment Fund, GMO Climate Change Investment Fund, GMO Equity Dislocation Investment Fund, GMO Emerging Country Debt UCITS Fund, GMO Usonian Japan Value Fund, and GMO Resources UCITS Fund (the “Funds” and each a “Fund”) dated 23 February 2021 as amended or supplemented from time to time (the “Prospectus”).**

Information contained in this UK Country Supplement is selective and specific to UK investors. Words and expressions defined in the Prospectus, unless otherwise defined below, shall bear the same meaning when used herein.

The Financial Conduct Authority (the “FCA”) has not approved and takes no responsibility for the contents of the Prospectus or for the financial soundness of the ICAV or any of its sub-funds or for the correctness of any statements made or expressed in the Prospectus.

The ICAV is an EEA UCITS scheme which is recognised under Part 6 of The Collective Investment Schemes (Amendment etc.) (EU Exit) Regulations 2019, as may be amended (the “CIS”). Shares in the ICAV may be promoted to the UK public by persons authorised to carry on investment business in the UK and will not be subject to the restrictions contained in Section 238 of the Financial Services and Markets Act 2000.

The ICAV does not carry on investment business in the UK, so as to require the conduct of its business to be regulated by the FCA. Shareholders are therefore unlikely to have access to the Financial Ombudsman Service and may also not benefit from the rights under the Financial Services Compensation Scheme. Shareholders may wish to obtain independent professional advice if they are in any doubt as to their eligibility.

Shareholders’ attention is drawn to the section of the Prospectus entitled “Fees and Expenses”.

Shareholders’ attention is also drawn to the section of the Prospectus entitled “Certain U.K. Tax Considerations”. Prospective shareholders should consult their own tax advisers regarding the UK tax consequences of an investment in the Funds.

#### **UK Facilities Agent**

In connection with the ICAV’s recognition under Part 6 of the CIS, the ICAV has appointed GMO UK Limited as its facilities agent (“**Facilities Agent**”) to maintain the facilities required of a recognised scheme pursuant to the rules contained in the FCA Handbook of Rules and Guidance governing recognised schemes.

The facilities are located at the offices of GMO UK Limited at No.1 London Bridge, London, SE1 9BG, England. At these facilities, any person may:

- 1) inspect (free of charge) a copy (in English) of:
  - a) the instrument of incorporation of the ICAV;
  - b) the latest version of the Prospectus;
  - c) the latest version of the key investor information documents of the Funds; and
  - d) the latest annual and half-yearly reports;
- 2) obtain a copy of any of the above documents (free of charge in the case of documents b) to d));
- 3) obtain information (in English) about the prices of Shares in the Funds; and
- 4) make a complaint about the operation of the ICAV, which the Facilities Agent will transmit to the ICAV.

Further, any Shareholder may redeem or arrange for the redemption of Shares in the Funds and obtain payment at the offices of the Facilities Agent.